Trevi Therapeutics Stock News & Updates

[WKN: A2PHHF | Symbol: TRVI]

Trevi Therapeutics

Trevi Therapeutics: Analysts See Great Opportunities for Haduvio After GSK Setback

07/20/2026 at 01 PM

GE Aerospace [US3696043013] UBS confirms Buy rating and raises price target from 426 to 435 USD (25%...

07/16/2026 at 10 AM

Trevi Therapeutics has approximately $334 million in liquid assets thanks to successful capital increases,...

11/14/2025 at 01 PM

Paysign [US70451A1043] Lake Street confirms Buy rating with a price target of $10 (83% upside potential)...

08/21/2025 at 04 PM

Trevi Therapeutics Inc. (TRVI) is a clinical-stage biopharmaceutical company developing the investigational...

08/21/2025 at 12 PM

Axsome Therapeutics [US05464T1043] RBC Capital confirms Buy rating with a price target of $189...

05/28/2025 at 02 PM

BWX Technologies [US05605H1005]: CLSA reiterates Outperform rating and raises the price target from $153...

03/11/2025 at 03 PM

Trevi Therapeutics (TRVI) is a biotech company focusing on the development of Haduvio (oral Nalbuphine...

03/10/2025 at 01 PM

Samsara [US79589L1061] Piper Sandler upgrades from Neutral to Overweight with a price target of $50 (40%...